Aflibercept Patent Expiration
Aflibercept Large Molecule Patents
Given below is the list of large molecule patents protecting Aflibercept, along with the drug name that holds that patent and the company name owning that drug.
| Drug Used in | Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Drug Owner |
|---|---|---|---|---|
| Eylea | USUS10973879 | Use of a VEGF antagonist to treat angiogenic eye disorders | May 17, 2039 | Regeneron Pharmaceuticals, Inc. |
| Eylea | USUS11577025 | Devices and methods for overfilling drug containers | Oct 06, 2037 | Regeneron Pharmaceuticals, Inc. |
| Eylea | USUS11433186 | Devices and methods for precision dose delivery | Dec 12, 2038 | Regeneron Pharmaceuticals, Inc. |
| Eylea | USUS11975045 | Use of a VEGF antagonist to treat angiogenic eye disorders | Jan 11, 2032 | Regeneron Pharmaceuticals, Inc. |
| Eylea | USUS7771997 | Enhanced expression and stability regions | Jul 02, 2028 | Regeneron Pharmaceuticals, Inc. |
| Eylea | USUSD906102 | Packaging | Dec 29, 2035 | Regeneron Pharmaceuticals, Inc. |
| Eylea | USUS9816110 | CHO integration sites and uses thereof | Oct 21, 2035 | Regeneron Pharmaceuticals, Inc. |
| Eylea | USUS9254338 | Use of a VEGF antagonist to treat angiogenic eye disorders | May 22, 2032 | Regeneron Pharmaceuticals, Inc. |
| Eylea | USUS10857205 | Use of a VEGF antagonist to treat angiogenic eye disorders | Jan 11, 2032 | Regeneron Pharmaceuticals, Inc. |
| Eylea | USUS11332771 | Serum-free cell culture medium | Mar 14, 2034 | Regeneron Pharmaceuticals, Inc. |
| Eylea | USUS9315281 | System and methods for use in dispensing biopharmaceutical materials | Sep 16, 2034 | Regeneron Pharmaceuticals, Inc. |
| Eylea | USUS11299532 | Anti-VEGF protein compositions and methods for producing the same | Aug 18, 2040 | Regeneron Pharmaceuticals, Inc. |
| Eylea | USUS11549154 | Compositions and methods for detecting a biological contaminant | Dec 25, 2036 | Regeneron Pharmaceuticals, Inc. |
| Eylea | USUS11555176 | Cell culture medium for eukaryotic cells | Jan 27, 2040 | Regeneron Pharmaceuticals, Inc. |
| Eylea | USUS11505593 | Anti-VEGF protein compositions and methods for producing the same | Aug 18, 2040 | Regeneron Pharmaceuticals, Inc. |
| Eylea | USUS10888601 | Use of a VEGF antagonist to treat angiogenic eye disorders | Jan 11, 2032 | Regeneron Pharmaceuticals, Inc. |
| Eylea | USUS11788102 | CHO integration sites and uses thereof | Sep 13, 2038 | Regeneron Pharmaceuticals, Inc. |
| Eylea | USUS9562238 | Enhanced expression and stability regions | Jun 04, 2028 | Regeneron Pharmaceuticals, Inc. |
| Eylea | USUS10669594 | Compositions and methods for detecting a biological contaminant | Feb 12, 2037 | Regeneron Pharmaceuticals, Inc. |
| Eylea | USUSD961376 | Packaging | Aug 23, 2037 | Regeneron Pharmaceuticals, Inc. |
| Eylea | USUS11559564 | Use of a VEGF antagonist to treat angiogenic eye disorders | Jan 11, 2032 | Regeneron Pharmaceuticals, Inc. |
| Eylea | USUS11084865 | VEGF antagonist formulations suitable for intravitreal administration | Jun 14, 2027 | Regeneron Pharmaceuticals, Inc. |
| Eylea | USUS11459374 | Anti-VEGF protein compositions and methods for producing the same | Aug 18, 2040 | Regeneron Pharmaceuticals, Inc. |
| Eylea | USUS11103552 | High concentration VEGF receptor fusion protein containing formulations | May 15, 2039 | Regeneron Pharmaceuticals, Inc. |
| Eylea | USUS11104715 | Methods for producing aflibercept in chemically defined media having reduced aflibercept variants | Aug 18, 2040 | Regeneron Pharmaceuticals, Inc. |
| Eylea | USUS11535663 | Methods for producing aflibercept in chemically defined media having reduced aflibercept variants | Aug 18, 2040 | Regeneron Pharmaceuticals, Inc. |
| Eylea | USUS11053280 | Anti-VEGF protein compositions and methods for producing the same | Aug 18, 2040 | Regeneron Pharmaceuticals, Inc. |
| Eylea | USUS9222106 | Enhanced expression and stability regions | Jun 04, 2028 | Regeneron Pharmaceuticals, Inc. |
| Eylea | USUS10130681 | Use of a VEGF antagonist to treat angiogenic eye disorders | Jan 11, 2032 | Regeneron Pharmaceuticals, Inc. |
| Eylea | USUS11160918 | Medical device packaging and related methods | Jul 29, 2039 | Regeneron Pharmaceuticals, Inc. |
| Eylea | USUS11525833 | Hydrophobic interaction chromatography-coupled native mass spectrometry for antibody analysis | Nov 29, 2040 | Regeneron Pharmaceuticals, Inc. |
| Eylea | USUS11680930 | Methods and systems for chromatography data analysis | Oct 25, 2037 | Regeneron Pharmaceuticals, Inc. |
| Eylea | USUS11306135 | Anti-VEGF protein compositions and methods for producing the same | Aug 18, 2040 | Regeneron Pharmaceuticals, Inc. |
| Eylea | USUS9932605 | Enhanced expression and stability regions | Jun 04, 2028 | Regeneron Pharmaceuticals, Inc. |
| Eylea | USUS11485770 | Anti-VEGF protein compositions and methods for producing the same | Aug 18, 2040 | Regeneron Pharmaceuticals, Inc. |
| Eylea | USUS11174283 | Anti-VEGF protein compositions and methods for producing the same | Aug 18, 2040 | Regeneron Pharmaceuticals, Inc. |
| Eylea | USUS10415055 | Enhanced expression and stability regions | Jun 04, 2028 | Regeneron Pharmaceuticals, Inc. |
| Eylea | USUS10927342 | Taurine supplemented cell culture medium and methods of use | Aug 03, 2036 | Regeneron Pharmaceuticals, Inc. |
| Eylea | USUS11918785 | Devices and methods for overfilling drug containers | Jun 29, 2037 | Regeneron Pharmaceuticals, Inc. |
| Eylea | USUS7070959 | Modified chimeric polypeptides with improved pharmacokinetic properties |
Jun 16, 2023
(Expired) | Regeneron Pharmaceuticals, Inc. |
| Eylea | USUS11850407 | Needle shield grip devices and related methods | Sep 18, 2039 | Regeneron Pharmaceuticals, Inc. |
| Eylea | USUS11707506 | Use of a VEGF antagonist to treat angiogenic eye disorders | Jun 03, 2032 | Regeneron Pharmaceuticals, Inc. |
| Eylea | USUS11459373 | Anti-VEGF protein compositions and methods for producing the same | Aug 18, 2040 | Regeneron Pharmaceuticals, Inc. |
| Eylea | USUS11186625 | Anti-VEGF protein compositions and methods for producing the same | Aug 18, 2040 | Regeneron Pharmaceuticals, Inc. |
| Eylea | USUS11732025 | Anti-VEGF protein compositions and methods for producing the same | Aug 18, 2040 | Regeneron Pharmaceuticals, Inc. |
| Eylea | USUS11793926 | Medical device packaging and related methods | Jul 29, 2040 | Regeneron Pharmaceuticals, Inc. |
| Eylea | USUSD1035436 | Packaging |
Jul 16, 2024
(Expired) | Regeneron Pharmaceuticals, Inc. |
| Eylea | USUS11548932 | Anti-VEGF protein compositions and methods for producing the same | Aug 18, 2040 | Regeneron Pharmaceuticals, Inc. |
| Eylea | USUS11439758 | Devices and methods for precision dose delivery | Jun 04, 2040 | Regeneron Pharmaceuticals, Inc. |
| Eylea | USUS10464992 | VEGF antagonist formulations suitable for intravitreal administration | Jun 14, 2027 | Regeneron Pharmaceuticals, Inc. |
| Eylea | USUS11732024 | VEGF antagonist formulations suitable for intravitreal administration | Jun 14, 2027 | Regeneron Pharmaceuticals, Inc. |
| Eylea | USUS11312936 | Taurine supplemented cell culture medium and methods of use | Aug 03, 2036 | Regeneron Pharmaceuticals, Inc. |
| Eylea | USUS11478588 | Needle shield grip devices and related methods | Jul 25, 2040 | Regeneron Pharmaceuticals, Inc. |
| Eylea | USUS11986511 | Use of a VEGF antagonist to treat angiogenic eye disorders | Jan 11, 2032 | Regeneron Pharmaceuticals, Inc. |
| Eylea | USUS10828345 | Use of a VEGF antagonist to treat angiogenic eye disorders | Jan 11, 2032 | Regeneron Pharmaceuticals, Inc. |
| Eylea | USUS11066458 | VEGF antagonist formulations suitable for intravitreal administration | Jun 14, 2027 | Regeneron Pharmaceuticals, Inc. |
| Eylea | USUS11769597 | Methods of associating genetic variants with a clinical outcome in patients suffering from age-related macular degeneration treated with anti-VEGF | Dec 04, 2038 | Regeneron Pharmaceuticals, Inc. |
| Eylea | USUS10905786 | Sterilisation method | Mar 06, 2038 | Regeneron Pharmaceuticals, Inc. |
| Eylea | USUS11753459 | Anti-VEGF protein compositions and methods for producing the same | Aug 18, 2040 | Regeneron Pharmaceuticals, Inc. |
| Eylea | USUS10857231 | Formulations of VEG antagonist fusion proteins and method of manufacturing them |
(Expired) | Regeneron Pharmaceuticals, Inc. |
| Eylea | USUSD858754 | Syringe cap | Sep 03, 2034 | Regeneron Pharmaceuticals, Inc. |
| Eylea | USUS11253572 | Use of a VEGF antagonist to treat angiogenic eye disorders | Jan 11, 2032 | Regeneron Pharmaceuticals, Inc. |
| Eylea | USUS9669069 | Use of a VEGF antagonist to treat angiogenic eye disorders | Jan 11, 2032 | Regeneron Pharmaceuticals, Inc. |
| Eylea | USUSD934069 | Packaging | Oct 26, 2036 | Regeneron Pharmaceuticals, Inc. |
| Eylea | USUS10918754 | Sterilisation method | Mar 06, 2038 | Regeneron Pharmaceuticals, Inc. |
| Eylea | USUSD961377 | Packaging | Aug 23, 2037 | Regeneron Pharmaceuticals, Inc. |
| Eylea | USUS10406226 | Method of manufacturing VEGF antagonist fusion proteins | Mar 22, 2026 | Regeneron Pharmaceuticals, Inc. |
| Eylea | USUS11542317 | Anti-VEGF protein compositions and methods for producing the same | Aug 18, 2040 | Regeneron Pharmaceuticals, Inc. |
| Eylea | USUS11268109 | CHO integration sites and uses thereof | Oct 21, 2035 | Regeneron Pharmaceuticals, Inc. |
| Eylea | USUS10182969 | Aseptic piercing system and method | Jul 13, 2037 | Regeneron Pharmaceuticals, Inc. |
| Eylea | USUS11472861 | Methods for producing aflibercept in chemically defined media having reduced aflibercept variants | Aug 18, 2040 | Regeneron Pharmaceuticals, Inc. |
| Eylea | USUS11970724 | Serum-free cell culture medium | Mar 14, 2034 | Regeneron Pharmaceuticals, Inc. |
Aflibercept's Family Patents
Explore Our Curated Drug Screens
Drugs Generating Over $1 Billion in Annual Revenue
Explore the top-performing drugs that dominate the pharmaceutical industry
View List
NCE-1 Patent Expiry in the Next 1 Year
Identify opportunities as new chemical entity (NCE-1) patents approach expiry
View List
Recently Granted Patents in EP
Find the opportunity to file Oppositions
View List